| INTRODUC TI ON
The T cell receptor (TCR) plays a decisive role in host T-cell responses to cognate antigen through its variable regions and the properties they confer on each individual receptor (Smith et al., 2013) . The TCR also contributes to T cell function through its membrane proximal regions that interact with other components of the TCR/CD3 complex to drive signaling through MEKK1 and MAP kinase pathways (van Panhuys, 2016) . As a readout of T cell activation, investigators have generally turned to IFN-γ secretion (Meng et al., 2016) . However, a recent body of work supports a critical role for IL-17-secreting T cells in defining the longevity and versatility of cytotoxic T cell populations responding to cognate antigen, suggesting that IFN-γ secretion alone will not adequately define superior T cell activation (Nelson et al., 2015) .
One area where superior TCR activation is of particular importance is in tumor immunotherapy. T cell receptors specific for tumor antigens offer therapeutic potential (Golubovskaya, Berahovich, Xu, Harto, & Wu, 2017) . By cloning such receptors, we can generate reagents to redirect T cells toward the tumor and activate immune responses in patients who do not develop adequate reactivity to keep the tumors in check. For example, TCR transgenic T cells targeting melanosomal differentiation antigens are currently in clinical trials for the treatment of malignant melanoma (Chodon et al., 2014) . The first published trial of its kind was reported in 2006, using the F5 receptor against human MART-1 (Duval et al., 2006) . The results were encouraging, and several investigators are currently pursuing T cell receptors for tumor-directed therapy, which appears to be associated with fewer severe side effects than T cells bearing chimeric antigen receptor transgenes (Ataca & Arslan, 2015) .
In a general sense, understanding the role of TCRs in T cell activation is central to their biology. For therapeutic applications, TCRs with high affinity for relevant antigens can be identified through measurements that quantify binding affinities, or through functional parameters such as cytotoxicity toward target cells, proliferation of the T cells, or expression of representative cytokines (Hebeisen et al., 2015) . As T cells are front and center in type 1 responses, IFN-γ has taken a prominent role as the prime cytokine to identify T cells and TCRs with optimal avidity or affinity toward their cognate antigen.
To challenge the hypothesis that TCR affinity and subsequent IFN-γ release define the optimal T cells and TCRs, we studied three receptors that mediate reactivity toward a single antigenic peptide presented in the context of the same HLA-A*0201 molecule. TCR constructs were generated that defined expression of each TCR in an identical fashion, cloning each TCR into the same retroviral vectors with subunits separated by the same P2A viral slippage sequence, and introduced them into CD8 T cells from the same donors. Once each TCR was transduced in primary human T cells from these donors, we originally compared each TCR transgenic T cell population based on the amount of IFN-γ secreted in response to the gp100 antigen (Moore et al., 2009 ) and in response to naturally processed peptide. As differences in TCR stability may affect the level of TCR expression at the cell surface, which in turn affects T cell avidity, we measured the amount of TCR expression using antibodies to the TCR-β subunit. We next measured the classic IFN-γ secretion patterns in response to a range of peptide concentrations and related these to binding affinities determined using biochemical assays with recombinant molecules. We included analysis of IL-17A, a cytokine that may define the longevity of responses in vivo supported by signaling via the inducible costimulatory molecule called ICOS (Nelson et al., 2015) . The phenotype and function of cytokine secreting cells were further defined by flow cytometry and cytokine array. To understand which TCR would define optimal responses toward tumor cells in vivo, we performed efficacy studies in SCID/beige immunodeficient mice challenged with 888-A2 + T cells, comparing tumor growth among groups of mice treated with transgenic CD8 T cells. The link between cytokine expression patterns and in vivo responsiveness to our TCR constructs was then further examined by modeling the position of each TCR in complex with the gp100/HLA-A2 complex. The striking differences in responsiveness of T cells from the same donors that express TCRs that respond to the same peptide-HLA complexes help us define the role of the TCR in T responsiveness and suggest parameters that will better predict the reactivity of host T cells when selecting T cells to be used in therapeutic settings.
| MATERIAL S AND ME THODS

| Cell lines
T2 cells were obtained from the American Type Culture Collection (VA, USA) and maintained in RPMI 1640 medium (Mediatech, VA, USA) with 10% heat-inactivated fetal bovine serum (Atlanta Biologicals, GA, USA), 250 ng/ml amphotericin B, 100 U/ml penicillin, 100 μg/m streptomycin (Invitrogen, CA, USA), and 2 mM L-glutamine (Invitrogen, CA, USA). Cells were grown at 37°C and 5% CO 2 .
GP2-293 viral producing cells, retroviral vector pQCXIN, and pVSV-g were obtained from Clontech Laboratories, Inc (CA, USA), and cells were maintained in Dulbecco's modified Eagle's medium (Mediatech, VA, USA) with 10% heat-inactivated fetal bovine serum (Atlanta Biologicals, GA, USA), 250 ng/ml amphotericin B, 100 U/ml penicillin, 100 μg/ml streptomycin (Invitrogen), 4.5 g/L L-glutamine, 4.5 g/L glucose, and 4.61 g/L sodium pyruvate (Mediatech, VA, USA). Transfected GP2-293 was maintained in the presence of 2 mg/ ml G418 sulfate (Mediatech, VA, USA).
T cells purified from PBMCs were maintained in AIMV medium (Invitrogen, CA, USA) supplemented with 5% heat-inactivated pooled human AB serum (Sigma, VA, USA), 250 ng/ml amphotericin B, 100 U/ml penicillin, 100 μg/ml streptomycin (Invitrogen, CA, USA), 300 IU/ml recombinant human IL-2, 100 ng/ml recombinant IL-15 (both R&D Systems, MN, USA), and 50 ng/ml OKT3 (eBioscience, CA, USA). PBMCs from healthy apheresis patients were isolated by Ficoll gradient centrifugation unless otherwise noted.
Melanocytes isolated from foreskin were plated in Ham's F-12 medium (Mediatech, VA, USA) with 2 mmol/L-glutamine, 100 IU/ ml penicillin, 100 mg/ml streptomycin, 100 mg/ml amphotericin, (Klarquist et al., 2016; Rivoltini et al., 1995; Zhai et al., 1996) were maintained as described for GP293 cells above.
| Retroviral vector construction and transduction
Retroviral vector pQCXIN (Clontech, CA, USA) served as a backbone for transductions. TCR α-and β-chains for T cell clones SILv44, T2H4, or R6C12 (Klarquist et al., 2016; Moore et al., 2009) For T-cell transduction, PBMCs were activated in culture medium for 3 days. Nonadherent cells were negatively sorted for CD8 T cells (Stem Cell Technologies, BC, Canada) and transduced twice, one day apart using the retronectin-retrovirus method before selection in 1 mg/ ml G-418 sulfate for 5 days. Transduced T cells were rapidly expanded using a 200-fold excess of 5,000 rad irradiated feeders for 5 days.
| Flow cytometry
Cells were stained with fluorochrome-conjugated anti-CD3-FITC, anti-CD4-V450, anti-CD8-PE-Cy7 (all BD Biosciences, CA, USA), anti-Vβ8-PE, anti-Vβ17-PE (both Beckman Coulter, CA, USA). Data were collected on a Fortessa LSR II instrument (BD Biosciences).
| Cytokine release assays
In cytokine release assays, 1x10
5 effector T cells were combined with T2 target cells at 1:1 in a 96-well U-bottom plate for 20 hr. T2 target cells were either unpulsed or peptide-pulsed for two hours prior to incubation with effectors. Cytokine release in the supernatant was measured using an ELISAPRO kit for INF-γ or IL-17A ELISA (Mabtech, OH, USA).
| Antitumor efficacy of TCR-transduced T cells in vivo
Therapeutic responses were measured in vivo, following subcutaneous injection of 10 6 human 888-A2 + into SCID/beige mice (n = 4). 
| Binding affinity measurements
Soluble constructs of SILv44, R6C12, T4H2, and HLA-A2 were expressed and refolded as described (Davis-Harrison, Armstrong, & Baker, 2005) . Briefly, the TCR α-and β-chains, the HLA-A2 heavy chain, and β 2 -microglobulin (β 2 m) were expressed separately in Escherichia coli. Isolated inclusion bodies were dissolved in 8 M urea.
For TCR refolding, TCR α-and β-chains with α-chain in 20% excess were rapidly diluted into 50 mM Tris-HCl (pH 8.3), 2.5 M urea, 6.3 mM cysteamine, 3.7 mM cystamine, 2 mM EDTA, and 0.2 mM PMSF with the addition of 400 mM ʟ-arginine for SILv44 and R6C12.
HLA-A2 heavy chain and β 2 m were rapidly diluted into 100 mM Tris-HCl (pH 8.3), 400 mM ʟ-arginine, 6.3 mM cysteamine, 3.7 mM cystamine, 2 mM EDTA, and 0.2 mM PMSF in a 1:3 molar ratio with excess peptide. TCR and peptide/MHC complexes were incubated for 12 hr at 4°C. TCR and peptide/MHC complexes were dialyzed against 10 mM Tris-HCl (pH 8.3) for 48 hr. Folded complexes were purified via anion exchange followed by size-exclusion chromatography. Steady-state binding experiments were performed with a Biacore T200 as described (Davis-Harrison et al., 2005) . Briefly, experiments were performed at 25°C in HBS-EP buffer containing 10 mM HEPES, 3 mM EDTA, 150 mM NaCl, and 0.0005% surfactant P20 at pH 7.4. TCR was immobilized on a CM5 sensor chip using standard amine coupling to final response units between 700 and 3,000. Peptide/MHC complexes were injected at a flow rate of 10 μl/min until steady-state was reached. The concentration range of peptide/MHC complexes spanned from 13 nM to 300 μM. The signal over the final 10 seconds of injection was averaged and subtracted from identical injections over a mock surface. Each injection was performed in duplicate and fit simultaneously, using global analysis to enhance accuracy and precision (Blevins & Baker, 2017) .
Data were processed using BiaEvaluation 4.0 and fit with Origin 2017 using a 1:1 binding model. Six experiments were performed for SILv44 and R6C12 and five experiments for T4H2.
| Modeling of TCR-peptide/MHC complexes
TCR-peptide/MHC structural models were constructed using a template-based approach described recently (Riley et al., 2016 (Borbulevych, Santhanagopolan, Hossain, & Baker, 2011) was selected as the template for the R6C12 and T4H2 models, and the B7-Tax/HLA-A2 complex (Ding et al., 1998) was chosen for SILv44.
Using PyRosetta, a python toolkit for the Rosetta protein design suite (Chaudhury, Lyskov, & Gray, 2010; Kaufmann, Lemmon, Deluca, Sheehan, & Meiler, 2010) , the given TCR sequences and peptides were mapped onto the three-dimensional coordinates of the template TCRs and peptides in the TCR-peptide/MHC complexes. Repacking the amino acid side chains and an energetic minimization of the CDR loops/peptides generated initial models of the target TCRs. Further design work performed in Rosetta followed a steepest descent design where many independent decoy structures were generated for each modeling stage. Each model underwent one stage for low-resolution docking, one stage for high-resolution docking, and multiple stages for CDR loop modeling. Using a previously described energy scoring function (Leaver-Fay et al., 2013) , the lowest scoring decoys from each stage were chosen for the next step. Following generation of an initial TCR-peptide/MHC model, 10,000 decoys were generated with fully randomized peptide/MHC and TCR docking orientations coupled with a low-resolution rigid body energy minimization move. Since many decoys generated in this stage were low scoring, preference was given to structures with crossing angles similar to the template. After the low-resolution docking stage, loop randomization and modeling were performed as previously described with generation of 100 decoys for each CDR loop (Mandell, Coutsias, & Kortemme, 2009 ). The first round of loop modeling was followed by generation of 10,000 decoys with 3 Å, 8° rigid body perturbations and docked in high resolution. The final stages consisted of sequentially modeling each modified CDR loop until Rosetta scores were no longer decreasing between stages.
The final model of R6C12 required 20 stages, SILv44 required 18, and T4H2 required only 13 stages due to a high template similarity.
Structural analysis was performed with PyMol and Discovery Studio.
| Statistics
Student's t test was used to compare relevant datasets, using twosided comparisons for normally distributed data unless otherwise indicated. For in vivo experiments, a generalized estimating equation approach was used for making comparisons of growth rates across groups in a linear regression model with an assumed exchangeable correlation structure to account for repeated measures over time. Due to the nonlinear patterns of tumor size by day, we used the square root of volume as our outcome and day and indicators of group, and interactions between group and the day as our 
covariates. Robust Z-scores for the interaction terms were used to calculate p-values for comparisons of slopes across groups.
| RE SULTS
| TCR SILv44 preferentially imparts IL-17 responses on host T cells
Given the role for IFN-γ in antitumor responses (Candeias & Gaipl, 2016) , we initially examined secretion by CD8 T cells in response to increasing concentrations of the 2M-modified gp100 peptide with enhanced affinity for HLA-A2. In Figure 1a , the T4H2 TCR clearly displays superior reactivity toward peptide-pulsed T2 cells, with half-maximum IFN-γ secretion detected in response to 1.65 nM peptide as compared to 9.6 nM for R6C12 and 30 nM for SILv44.
The ranking of IFN-γ release was generally congruent with TCR binding affinity measured with recombinant protein using surface plasmon resonance (SPF), which yielded K D values of 1.8 ± 0.6 μM, 37 ± 13 μM and 155 ± 53 μM, respectively (Figure 1b) . Although the 2M-modified peptide used for the secretion assay matches the treatment provided to patients who gave rise to the T4H2 and R6C12 TCRs, the host rendering the SILv44 receptor had not been 
| TCR-dependent differences in cytokine profiles are fine-tuned by TCR stimulation
We next considered whether differences in T cell avidity driven either by TCR cell surface levels or by TCR affinity for the peptide-MHC complex could contribute to the cytokine production differences. and is consistent with the weaker binding of the wild-type versus modified peptide in the binding groove, the only reported difference between the two peptides (Borbulevych et al., 2005; Yu et al., 2004) . In contrast to IFN-γ production, we observed decreasing IL-17A production with increasing peptide concentration among all TCRs (Figure 3b ). Furthermore, subtle differences among the TCRs appear to show that in response to low concentrations comparable to those of naturally processed antigen, specifically at the 0.5 nM range, the SILv44 TCR drives relatively more IL-17 secretion than the other TCRs whereas T4H2 preferentially drives IFN-γ secretion.
Moreover, upon broader screening, other differences in response to 888-A2 + target cells were found that differentiate SILv44 from the TCRs (Supporting Information Figure S2 ). Taken together, these data suggest that the functional response of the T cells may be dictated by features beyond both antigen specificity and affinity of the peptide in the binding groove , the only reported difference between the two peptides, such as differences in the TCR variable region.
| IL-17A-producing SILv44-transduced T cells demonstrate superior in vivo tumor control
We next asked whether the distinct cytokine responses observed among the TCRs would translate to differential tumor control in vivo. pretreatment differences in tumor size, the average fold change in tumor size relative to treatment day 1 is depicted; results are shown for two separate experiments to account for interexperimental variation (Figure 4a,b) . Very similar growth curves were observed in both experiments, and significant inhibition of tumor growth was observed only for SILv44 transduced T cells compared to mice receiving untransduced T cells as listed underneath the growth curves.
Moreover, tumors treated with SILv44-expressing T cells revealed marked necrosis (data not shown), suggesting that this TCR affected tumor cell viability to a greater extent than is reflected by tumor sizes alone. However, when we compared T cell infiltration and transgenic TCR Vβ expression (Figure 4c,d) , we observed no differences among groups, suggesting that the quality of the cellular response rather than the quantity of intratumoral antigen-specific T cells may be 
| Structural models of the TCR-peptide/MHC complexes predict different TCR binding architectures
To explore possible underpinnings of the differential cytokine expression and associated outcomes with the three TCRs, and SILv44 in particular, we generated models of the three TCR-peptide/MHC complexes using a template-based approach that combines loop and peptide modeling with low-and high-resolution docking procedures.
We previously demonstrated this modeling procedure can reproduce key structural features such as interface contacts and TCR docking modes (Riley et al., 2016) . After identifying appropriate template structures for T4H2, R6C12, and SILv44, the TCRs and peptides were computationally morphed and several rounds of structural and energetic refinement were applied. The complexes were subsequently subjected to multiple rounds of randomized low-resolution docking, high-resolution interface refinement, and restrained highresolution docking. An overview of the resulting structural models is shown in Figure 5a . The most striking observation is the altered mode of engagement predicted for SILv44 compared to T4H2 and R6C12. As summarized in Figure 5b , although all three TCRs have similar crossing angles over the gp100 209-2M /HLA-A2 complex (24-44°, within the range of TCR complexes with class I proteins) (Rudolph, Stanfield, & Wilson, 2006; Wucherpfennig, Call, Deng, & Mariuzza, 2009) , the model of the SILv44 complex has a substantially different incident angle (18° versus 2-3°), resulting in a more 'tilted' complex. Beyond the gross topological difference, this altered mode of engagement impacts overall interface features. We focused on the central p4 glutamine of the gp100 209-2M peptide, which in the unbound gp100 209-2M /HLA-A2 complex protrudes up from the peptide backbone (Borbulevych et al., 2005; Riley et al., 2016) . Although the peptide conformation in each complex is predicted to be similar (Figure 5c ), the three TCRs engage pGln4 differently (Figure 5d ).
F I G U R E 5
Structural models of the T4H2, R6C12, and SILv44 TCRs with gp100 209-2M /HLA-A2. a, Overview of the complexes. In the three models, the T4H2 complex is magenta, R6C12 is cyan, and SILv44 is green (this coloring is maintained for all panels). The orientation of the peptide/MHC is the same in all three images. The altered binding mode predicted for SILv44 is clearly apparent. b, Quantification of TCR binding modes for the three complexes. The primary difference is in the incident angle, which is 18° off the vertical for SILv44, but 3° for R6C12 and 2° for T4H2. c, Conformations of the modeled peptides in the three TCR-peptide/MHC models, compared to the conformation of the peptide in the unbound gp100 209-2M /HLA-A2 crystal structure (white). The overall conformations are very similar, except for that with R6C12, in which pGln4 is predicted to be positioned more centrally in the TCR-peptide/MHC interface. d, Engagement of pGln4 in the three TCR-peptide/MHC models
Whereas SILv44 uses a positive charge from Arg95 in CDR3α, both T4H2 and R6C12 use only noncharged side chains to engage pGln4.
Burial of positive charges is often unfavorable, even when hydrogen bonds or salt bridges are formed (Hendsch & Tidor, 1994) , and this could contribute to the weaker affinity of SILv44 toward the 2M
antigen. Lastly, we observed that in the R6C12 complex, pGln4 is engaged by Asn99 of CDR3β (Figure 5d ). This is consistent with alanine scanning mutagenesis of this TCR, which revealed a greater role for CDR3β than CDR3α in ligand binding, and a role for Asn99β in particular (Malecek et al., 2013) . Thus, in silico modeling of the interaction of our TCRs with their cognate peptide predicted a different conformation for the combination that offered superior antitumor responses in vivo. Given the question of how differences in the TCR variable regions might influence downstream T cell signaling and cytokine responses, we turned to TCR in silico modeling, which predicted gross architectural differences between the complex formed by the SILv44 TCR and the R6C12/T4H2 TCRs with the 2M-modified peptide, whose conformation matches that of the wild-type peptide in the binding groove of the HLA-A2 molecule (Borbulevych et al., 2005; Yu et al., 2004) . TCR binding geometries impact T cell function (Adams et al., 2011; Gras et al., 2016) . Thus, differences 
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